Centaurus Financial’s Sinovac Biotech, Ltd SVA Stock Holding History

Centaurus Financial’s Portfolio SVA Stock Details SVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-12	Closed	–	–	2520
2018 Q2	$0	Buy	+12	New	+$94	﹤0.01%	2517

Other funds holding SVA

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

NAH

Neumann Advisory (HK) Central, Hong Kong $356M AUM 37.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SSP

Sapphire Star Partners Redmond, Washington $74.7M AUM 5.87% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

YMRC

Yorktown Management & Research Company Forest, Virginia $120M AUM 52.72% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

FIM

Freedom Investment Management Hartford, Connecticut $337M AUM 22.95% 1-Year Est. Return

Centaurus Financial's SVA Position: Q3 2018 in Review

Centaurus Financial sold out of Sinovac Biotech, Ltd (SVA) in Q3 2018, closing a stake of 12 shares.

Centaurus Financial first reported a position in SVA in Q2 2018 and held it in 1 quarter. The position peaked at $0 in Q2 2018. 28 funds tracked by Wall St. Rank hold SVA as of Q3 2018.

Centaurus Financial reported no remaining Sinovac Biotech, Ltd position as of Q3 2018 after selling out during the quarter.
Centaurus Financial sold 12 Sinovac Biotech, Ltd shares in Q3 2018.
Centaurus Financial first reported a position in Sinovac Biotech, Ltd in Q2 2018 and held it in 1 quarter.
Centaurus Financial's Sinovac Biotech, Ltd position peaked at $0 in Q2 2018.
28 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q3 2018.

Based on Centaurus Financial's 13F filing for Q3 2018, filed 5 Nov 2018.